a b s t r a c t NMDA Receptors (NMDARs) play key roles in synaptic physiology and NMDAR hypofunction has been implicated in various neurological conditions. In recent years an increasing number of positive allosteric modulators (PAMs) of NMDARs have been discovered and characterized. These diverse PAM classes vary not only in their binding sites and GluN2 subunit selectivity profiles, but also in the nature of their impacts on channel function. Major differences exist in the degree of slowing of channel deactivation and shifting of apparent agonist affinity between different classes of PAMs. Here we review the diverse modes of potentiation by the currently known classes of NMDAR PAMs and discuss the potential consequences of different types of potentiation in terms of desirable and undesirable effects on brain function.
Introduction
Glutamate (Glu) is the principle excitatory neurotransmitter in the brain. When released within the synaptic cleft, Glu binds to both ionotropic and metabotropic receptors, which results in activation and/or modulation of the post-synaptic neuron. Three main classes of ligand-gated ionotropic glutamate receptors exist that are defined by the pharmacology of their Glu binding sites: alphaamino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors (AMPARs), kainate receptors (KARs), and N-methyl-Daspartate (NMDA) receptors (NMDARs) (Traynelis et al., 2010) . While AMPARs and KARs are primarily involved in Glu-dependent depolarization at excitatory synapses, NMDARs play a special role as coincidence-detectors, allowing channel opening and depolarization as well as calcium influx only when the presence of Glu within the synaptic cleft coincides with depolarization of the postsynaptic membrane. As such, NMDARs play critical roles in learning, memory, and cognitive function in general.
NMDARs are large tetrameric ion channels that contain two GluN1 subunits and two GluN2 subunits (in some cases a GluN3 subunit can also be incorporated to form unconventional NMDARs). Each subunit contains a transmembrane domain (TMD), where the ion conductive pore and gating structures are located, a ligand binding domain (LBD) that contains the agonist binding sites, and an amino terminal domain (ATD). GluN2 LBDs contain the Glu binding site, while GluN1 (or GluN3) LBDs contain the Glycine/Dserine coagonist binding site. Four types of GluN2 subunits exit that have distinct spatial and temporal expression patterns in the CNS: GluN2A, GluN2B, GluN2C, and GluN2D (Akazawa et al., 1994; Laurie and Seeburg, 1994; Monyer et al., 1994; Standaert et al., 1994; Watanabe et al., 1992 Watanabe et al., , 1994 . GluN2B and GluN2D are the prominent NMDARs in the prenatal mouse brain whereas GluN2A and GluN2C are mostly not expressed until after birth. In the adult, GluN2C is most highly expressed in the cerebellum, replacing cerebellar GluN2B during early development. GluN2A slowly increases in expression in the cortex, hippocampus, and cerebellum starting soon after birth while GluN2B remains expressed throughout the brain, with the exception of the cerebellum, into adulthood. GluN2D decreases in expression during early development, but retains expression in subcortical regions and the brainstem in the adult. In addition to the distinct spatial and temporal expression patterns of the different GluN2 subunits, they also display significant functional differences, particularly in the rate of deactivation following removal of Glu. GluN2A shows the fastest deactivation kinetics, with a tau_deact <10 msec, GluN2B and GluN2C show intermediate deactivation kinetics (tau_deact around 200e400msec) , and GluN2D shows the slowest deactivation (tau_deact > 1000 msec) (Paoletti et al., 2013; Traynelis et al., 2010) .
Dysfunction of NMDAR signaling has been implicated in a variety of neurological and psychiatric disorders and thus there is growing interest in developing novel drugs that target these receptors (Paoletti et al., 2013; Soto et al., 2014; Zhou and Sheng, 2013) . Whereas excessive NMDAR activation is thought to play a pathological role in certain situations, such as in stroke and some neurodegenerative diseases, hypofunction of NMDARs may play an important role in the pathophysiology of other diseases such as schizophrenia. This idea originally arose from observations that NMDAR antagonists can transiently induce the positive, negative, and cognitive symptoms of schizophrenia in healthy individuals (Javitt and Zukin, 1991; Krystal et al., 1994) . Further studies have found reduced expression of NMDARs (in particular the GluN2A subunit) in parvalbumin (PV)-expressing interneurons in postmortem samples of schizophrenia patients (Akbarian et al., 1996; Bitanihirwe et al., 2009 ). In addition, transgenic mice with reduced GluN1 expression show schizophrenia-like behaviors (Mohn et al., 1999) . Of particular note, many of the schizophrenia behaviors identified in mice with globally reduced GluN1 function can be reproduced in mice with deletion of GluN1 subunits specifically from corticolimbic interneurons (Belforte et al., 2010) , suggesting that deficient NMDA function in interneurons may be sufficient to drive the pathophysiology of schizophrenia. Consistent with this idea, NMDAR inhibition leads to decreased expression of PV within PV interneurons (Behrens et al., 2007; Kinney et al., 2006) , and decreased PV levels are observed in post-mortem schizophrenia brain samples (Hashimoto et al., 2003) . Cumulatively this evidence has led to the hypothesis that interneuron NMDAR hypofunction plays a central role in schizophrenia (Gonzalez-Burgos and Lewis, 2012) . At the same time mutations of NMDAR subunits including predicted loss-of-function mutations have been identified in epilepsy patients (Carvill et al., 2013; Lemke et al., 2013; Lesca et al., 2013; Yuan et al., 2015) and impaired synaptic NMDAR function occurs in animal models of Alzheimer's Disease (Zadori et al., 2014) , raising the possibility that these indications may also involve NMDAR hypofunction.
Given that NMDAR hypofunction might play a role in the pathophysiology of certain nervous system disorders, pharmacologically increasing NMDAR activity could provide a therapeutic benefit. Compounds that act as agonists and directly activate NMDARs, however, induce severe toxicity, including seizures and neuronal death. Thus a major focus has been to identify compounds that indirectly increase NMDAR function in order to avoid the inherent toxicity associated with constitutive NMDAR activation. One therapeutic approach that has been extensively investigated for this purpose is inhibition of the GlyT1 glycine transporter (Dunlop and Brandon, 2015; Hashimoto, 2014) . Occupancy of the glycine (Gly) binding site on NMDARs is required for Gludependent activation of the receptor. While dynamic changes are not well studied, it is typically assumed that Gly and/or D-serine are tonically present at synapses in the brain where they act as coagonists and can modulate the function of NMDARs during synaptic Glu release. Thus increasing Gly concentrations by inhibition of GlyT1 should enhance Glu-dependent NMDAR synaptic currents. Similarly inhibiting degradation of D-serine by D-amino acid oxidase (DAAO) inhibitors has been explored as a means to enhance NMDAR currents (Sacchi et al., 2013) . Unfortunately, recent clinical trials of selective GlyT1 inhibitors have failed to show efficacy in schizophrenia patients, suggesting that GlyT1 transporters may not play a critical role in setting Gly levels at the specific synapses that are important for schizophrenia (Balu and Coyle, 2015) . Another indirect approach to enhancing NMDAR function has been selective positive allosteric modulators (PAMs) of mGluR5 metabotropic Glu receptors, which can indirectly lead to enhanced NMDAR function (Conn et al., 2014) . While mGluR5 PAMs show efficacy in animal models of schizophrenia, seizures and neurotoxicity have also been observed with some compounds, highlighting challenges with this approach (Yang et al., 2016) .
In recent years, several classes of compounds that act as direct PAMs of NMDA receptors have been identified (Zhu and Paoletti, 2015) . Such compounds represent an approach to enhancing NMDAR function that could be independent of the local Gly-site coagonist concentration and independent of intracellular signal transduction processes that indirect approaches to enhancing NMDAR function rely on. In this review, we will describe key properties of the different classes of NMDAR PAMs that have been identified. In addition to discussing subunit selectivity and potential binding sites, we will pay particular attention to different PAM modes of potentiation. We will then discuss how different properties of NMDAR PAMs could contribute to beneficial or detrimental effects in vivo.
Types of PAM effects
Positive allosteric modulators (PAMs) are defined as modulators that act to enhance the function of a receptor in the presence of agonist but are not able to directly activate the receptor in the absence of agonist. As such, PAMs can potentially avoid the toxicity associated with direct agonists since they preserve the natural pattern and timing of agonist-induced receptor activity while still increasing the function of the receptor. In principle, there are two types of PAM effects which can be detected in macroscopic NMDAR current measurements: 1) PAMs can act by enhancing the maximum activity or efficacy of a receptor without altering the agonist EC50, which we will refer to here as a type I PAM effect, and 2) PAMs can act by shifting the agonist EC50 to lower values, which we will refer to here as a type II PAM effect (Fig. 1a,c,e) . A key distinguishing aspect of PAMs that only have type II effects is that they don't enhance receptor function at saturating levels of agonist, whereas PAMs that only have type I effects enhance receptor function equally well at all agonist levels. In practice, PAMs may have a mixture of type I and type II activities. Our definitions of type I and type II PAM effects are based on readily observable effects on the macroscopic agonist dose-response relationship. While these empirical descriptions of type of PAM effects are useful for highlighting potentially physiologically relevant aspects of potentiation, it is important emphasize that the observation of type I and/or type II PAM effects does not imply an understanding of the underlying mechanisms of a PAM. Accordingly Type I and Type II effects as defined here should not necessarily be equated with changes in the specific kinetic parameters of mechanistic models of allostery (Colquhoun, 1998; Conn et al., 2009) .
There is an important consequence of the type II PAM effect, which is that, regardless of underlying mechanisms, PAMs with such effects will impact the macroscopic kinetics of receptor activation and/or deactivation. This is because deactivation and activation kinetics are related to agonist EC50 by mass action and it is expected that EC50 ¼ tau_act/tau_deact where tau_act and tau_-deact are the exponential time constants for activation and deactivation respectively. Thus the leftward shift in the EC50 of agonist that occurs in the presence of a type II effect implies that either activation is faster (smaller tau_act) or deactivation is slower (larger tau_deact) or both. In the case of NMDARs, slower deactivation kinetics will impact the length of time that synaptic NMDAR current flows following the rapid removal of Glu from the synaptic cleft and may dramatically affect the area under the curve of the NMDAR excitatory post synaptic current (EPSC) (Fig. 1b,d ,f). The effect of this is that more calcium influx will occur since the amount of calcium influx is proportional to the area under the curve of the NMDAR EPSC.
It should be pointed out that shifts in agonist EC50s caused by PAMs with type II effects do not necessarily imply direct allosteric interactions between the PAM binding site and the agonist binding site(s). For example, a PAM that enhances the current at saturating Glu but not the affinity of Glu can still in principle result in a leftward shift of the Glu EC50 curve. In the extreme case, a PAM capable of locking the channel in the open state (following natural Glu/Gly dependent activation) without altering Glu of Gly affinity would be expected to dramatically lower both Glu and Gly EC50s and slow deactivation kinetics (or prevent deactivation altogether). On the other hand, if there is a direct allosteric interaction between the PAM and agonist binding sites, the allosteric interaction should occur in a reciprocal fashion. Thus, a PAM that causes an increase in Glu affinity upon binding will see its own affinity enhanced in the presence of Glu. In this way, such a PAM will be sensitive to the steady-state resting synaptic Glu concentration that is present under physiological or pathophysiological conditions.
Classes of PAMs
Recently, increasing numbers of NMDAR selective PAMs have been discovered representing diverse structural classes (Fig. 2) . In this section we summarize information on the GluN2 subunit selectivity, proposed binding sites (Fig. 3) , and whether potentiation involves type I and/or type II effects for each major class of PAM.
PYD-106
One very well characterized NMDAR PAM series is the GluN2C-selective pyrrolidinone PAMs exemplified by PYD-106 (Fig. 2 ). This PAM series was originally identified by a high-throughput screen specifically looking for potentiators of GluN2C channels . Further studies revealed that PYD-106 functions as a PAM dominated by type I effects and is able to enhance GluN2D currents by 204% while only slightly altering the Glu EC50 . In fact, the Glu EC50 is slightly increased in the presence of PAM (rather than decreased as in the case a PAM with type II effects). At the single-channel level, PYD-106 increases the frequency of opening and the mean open time, thus indicating stabilization of the open state . Structural determinants of PYD-106 PAM effects were found nestled in the interface between the LDB and the ATD, which is a relatively poorly conserved part of the extracellular domain, explaining the high degree of selectivity for GluN2C. This region is altered by a common GluN1 splice variation and as a result, GluN2C receptors containing GluN1 exon-5 cannot be potentiated by PYD-106. Interestingly, pyrrolidinone PAMs are also selective for diheteromeric GluN1/GluN1/GluN2C/GluN2C receptors over GluN1/ GluN1/GluN2A/GluN2C triheteromeric receptors .
CIQ
The tetrahydroisoquinoline PAMs, typified by CIQ (Fig. 2) , is another well-characterized class of NMDAR PAM dominated by type I effects. This series was originally identified in a highthroughput screen of 100,000 compounds for their ability to potentiate either GluN2C or GluN2D NMDARs (Mullasseril et al., 2010) . As expected for a PAM with mostly type I effects, CIQ alters neither the Glu/Gly EC50s nor deactivation kinetics following Glu washout. Furthermore, CIQ is highly selective for GluN2C and GluN2D channels, showing no ability to potentiate either GluN2A or GluN2B. Further studies have demonstrated structural determinants of CIQ located in the transmembrane domain of GluN2C/D, where specific residues in the GluN2 M1 TM helix are critical to PAM action and affinity (Ogden and Traynelis, 2013) . Most of these residues are highly conserved between GluN2 subunits, though one residue, GluN2D Thr592 (or GluN2C Thr565), is an isoleucine residue in both GluN2A and GluN2B. The fact that CIQ fails to potentiate GluN2D receptors with a T592I mutation suggests that this single residue defines the NMDAR selectivity pattern. Residues in the linker between the S1 part of the LBD and the M1 helix (known as the pre-M1 region) also can alter the ability of CIQ to potentiate the channels when mutated, although these residues have been proposed to not make direct contacts with the PAM but rather alter the ability of CIQ to induce down-stream structural changes that alter channel gating. At the single-channel level, CIQ acts by increasing the opening frequency rather than by stabilizing the open-state of the channel (Mullasseril et al., 2010) .
Spermine
NMDARs are modulated by endogenous polyamines of which spermine is the most well studied (Fig. 2) . In addition to inhibiting NMDARs via a voltage-dependent pore block mechanism (Rock and MacDonald, 1992), spermine can potentiate NMDARs as well. The potentiation effect is specific to GluN2B, making spermine a GluN2B-selective NMDAR PAM, whereas the inhibitory effect of spermine occurs equally with all NMDARs. Spermine potentiates GluN2B by shifting the pH-dependence of proton inhibition of NMDARs (Traynelis et al., 1995) . As a result, spermine only potentiates GluN2B when the pH is in the physiological range (pH 6e8). Under conditions where pH > 8.0, spermine only functions as a pore blocker whereas when pH < 6.0, GluN2B is fully inhibited even in the presence of spermine. In addition to shifts in the pHdependence of proton inhibition, spermine also reduces the Gly EC50 by a factor of~3-fold without altering the Glu EC50 (Benveniste and Mayer, 1993; McGurk et al., 1990) . As expected, the deactivation kinetics following removal of Gly in the presence of saturating NMDA is slowed significantly in the presence of spermine, while the deactivation kinetics following removal of NMDA in the presence of Gly is not affected (Benveniste and Mayer, 1993) . Thus, spermine potentiates GluN2B receptors by two apparently distinct mechanisms. Since spermine causes an increase in Gly potency, its effects involve type II PAM action with respect to Gly. However, since Glu is the agonist that is rapidly removed from the synapse following synaptic release, deactivation kinetics should not be significantly altered physiologically. Therefore, spermine should be viewed as a PAM dominated by type I effects with respect to Glu. Extensive mutational analysis has demonstrated that structural determinants for spermine lie within the ATD at the lower lobe of the GluN1/GluN2B subunit interface (Mony et al., 2011) . Electrostatic interactions between charged residues present in the ATD lower lobe have been proposed to maintain the ATD in a state that favors a low open probability of the pore. By stabilizing the GluN1/ GluN2B interface at this lower lobe, spermine has been proposed to force the channel into a higher open probability state, thus causing potentiation (Mony et al., 2011) . Interestingly, the presence of exon-5 in the GluN1 ATD occludes the effects of spermine, making spermine specifically selective for GluN2B-containing NMDARs that lack exon-5 (Traynelis et al., 1995) .
Pregnenolone sulphate
In addition to modulation of GABAA receptors, neurosteroids can modulate NMDARs. Pregnenolone sulphate (PS) is the most widely studied neurosteroid potentiator of NMDARs (Fig 2) . Studies with oocyte NMDAR expression showed that PS potentiates GluN2A and GluN2B NMDARs and inhibits GluN2C and GluN2D NMDARs (Malayev et al., 2002) . Subsequent studies using rapid perfusion in HEK cells demonstrated additional complexity in the effects of PS on GluN2B NMDARs, with both inhibitory (with fast kinetics), and potentiating (with slower kinetics) effects observed (Horak et al., 2006) . Thus, subtype selectivity of pregnenolone might be the result of the balance between differential affinities for inhibitory and potentiating binding sites at NMDARs with different subunit compositions. In contrast, inhibitory neurosteroids, such as the related neurosteroid pregnanolone sulphate (3alpha5betaS) that inhibit all 4 GluN2 subtypes equally, would be predicted to bind primarily to the inhibitory site.
The location of the PS binding site that is responsible for PAM effects is still unclear, but appears to be distinct from the spermine binding site since unlike spermine, PS-dependent potentiation does not depend on pH nor the presence of the GluN1 exon-5 (Horak et al., 2006; Jang et al., 2004) , and PS is still capable of potentiating NMDARs in the presence of saturating concentrations of spermine (Park-Chung et al., 1997) . This evidence for distinct binding sites is consistent with the chemically distinct nature of the compounds with spermine being highly charged and PS very hydrophobic. The inhibitory neurosteroid binding site is also likely distinct from the PAM site since 3alpha5betaS inhibits with the same IC50 in the presence and absence of 200 mM PS (Park-Chung et al., 1997) . By generating a series of GluN2B/GluN2D chimeric constructs, subunit differences in the J and K helices present in the LDB were found to be responsible for the selectivity of PSdependent potentiation for GluN2B vs GluN2D (Horak et al., 2006; Jang et al., 2004) . It was thus proposed that the binding site might be at the GluN1-GluN2B subunit interface within the LBD. However, an alternative interpretation of existing data suggests a TMD binding site could also be possible (Mony et al., 2009) . Interestingly PS potentiation is much less effective when PS is applied in the presence of agonists, than when pre-applied before agonist application suggesting higher affinity binding to the inactive NMDAR conformation (Horak et al., 2004 (Horak et al., , 2006 . PS has been shown to increase both the NMDAR current at saturating agonists as well as the EC50s of Glu and Gly at GluN2A and GluN2B NMDARs, and has been shown to both increase the peak response during agonist application and significantly slow deactivation following agonist withdrawal (Bowlby, 1993; Ceccon et al., 2001; Horak et al., 2006; Malayev et al., 2002) . This indicates that PS functions as a mixed PAM with both type I and type II PAM effects.
Oxysterols
Aside from PS, another class of neurosteroid NMDAR PAMs is the oxysterol cholesterol derivatives (Fig. 2) . The oxysterol 24(S)-hydroxycholesterol (24(S)-HC) is the most abundant cholesterol metabolite found in the brain. 24(S)-HC, as well as its synthetic derivatives, SGE201 and SGE301, have been shown to be GluN2 subunit non-selective PAMs of NMDARs (Paul et al., 2013) . SGE-201 strongly increases the NMDAR current at saturating Glu and Gly, with only very minor effects on Glu potency (Linsenbardt et al., 2014) , and no appreciable slowing of deactivation is evident following agonist removal in the presence of 24(S)-HC or SGE-201 (Paul et al., 2013) , indicating that oxysterols act as non-selective NMDAR PAMs dominated by type I PAM effects. While little is known about the oxysterol binding site, lack of occlusion in pretreatment experiments suggests oxysterols may have a distinct binding site from PS, and action that appears to be consistent with first partitioning in to the plasma membrane could potentially suggest a TMD binding site (Linsenbardt et al., 2014; Paul et al., 2013) .
UBP compounds
A series of naphthoic and phenanthroic acids has been described to act as PAMs of certain NMDARs (Fig. 2) . The various compounds exhibit variable profiles of potentiation and inhibition of the different GluN2 subunits (Costa et al., 2010; Irvine et al., 2012) . For example, UBP512 causes a small potentiation of GluN2A NMDARs, has minimal effects on GluN2B, and inhibits GluN2C and GluN2D. UBP551 potentiates GluN2D while inhibiting GluN2A, GluN2B, and GluN2C. UBP710 and UBP714 potentiate GluN2A and GluN2B with minimal effects on 2C and 2D. UBP646 shows potentiation of all GluN2-containing NMDARs. Although the relatively low potency and limited solubility prevent full characterization of the selectivity of some of these compounds at saturating PAM concentrations, these compounds appear to reflect a binding site with rich potential for subunit selectivity. While a precise binding site has not been defined, based on potentiation of NMDARs with an ATD deletion and analysis of chimeric channels, a possible LBD binding site has been suggested. While it was shown that the NAM effects don't compete with Gly or Glu, insufficient data is available to determine if these compounds act via type I and/or type II PAM effects. However the observation that UBP512 potentiation of GluN2A
NMDARs is greater at saturating agonist concentrations compared to low agonist concentrations (Costa et al., 2010) is not consistent with type II effects and suggests potential type I effects.
GNE PAMs
Recently we described a novel series of NMDAR PAMs containing a thiazolo-pyrimidinone scaffold (Hackos et al., 2016; Volgraf et al., 2016) (Fig 2) . This series was identified in a highthroughput screen of 1.4 million compounds that were tested for their ability to potentiate GluN2A containing NMDARs. Further medicinal chemistry efforts led to the identification of GNE-6901 and GNE-8324 which show selectivity for GluN2A containing NMDARs and bind to the LBD at the GluN1-GluN2A subunit interface (Fig. 4a,c,d ). Interestingly, subtle chemical modifications led to the generation of PAMs dominated by type I PAM effects, such as GNE-6901, which only minimally increases Glu potency, as well as mixed PAMs with both type I and type II PAM effects such as GNE-8324, which significantly increase Glu potency (Fig. 5) . As expected, GNE-8324 significantly slows deactivation kinetics while GNE-6901 has only minimal effects on deactivation (Fig 5) . Interestingly, despite the fact that PAMs of this series bind to a site directly between the Glu and Gly binding sites within the LBD dimer, only Glu potency is affected.
The GluN2A subunit selectivity of the GNE PAMs is due to a single amino acid that is adjacent to the binding site, V783. This residue is valine in GluN2A, phenylalanine in GluN2B, and leucine in GluN2C and GluN2D. Steric clashes with the PAMs occur in the case of the larger phenylalanine and leucine side-chains, giving rise to the subtype selectivity. Interestingly, this same residue also contributes to the selectivity of TCN-201, a GluN2A-selective negative allosteric modulator (NAM) that binds to the same GluN1-GluN2A subunit-interface binding site (Hansen et al., 2012) . We recently solved a crystal structure of compound 6 (Bettini et al., 2010) , a close analog of TCN-201, in complex with the LBD, further verifying the location of the binding site for this class of NAM at the GluN1-GluN2A subunit interface within the LBD (Hackos et al., 2016) . TCN-201 is known to work by decreasing the potency of the GluN1 agonists Gly and D-serine (Edman et al., 2012; Hansen et al., 2012) , though it is not clear from the crystal structure how this happens exactly as the Gly binding site does not appear significantly perturbed upon NAM binding at the structural level (Fig. 4a,b) . The GNE PAMs, such as GNE-6901 and GNE-8324, bind to the same region but with a different orientation (Fig. 4c,d ). We speculate that by binding in this orientation, the PAMs stabilize the GluN1-GluN2A subunit interface in such a way to increase the open probability of the channel, even in the presence of saturating Glu and Gly (as is observed). How this occurs at the structural level, however, is not clear since we don't observe major differences between PAM-bound and un-bound structures. Furthermore, why some GNE PAMs such as GNE-8324 are able to increase the Glu potency while others such as GNE-6901 show minimal increases in Glu potency is also not clear from the structures. Interestingly, however, the GNE PAMs reposition the side chain of Y535, a residue in GluN1 that is thought to stabilize the Glu-bound state and alter Glu EC50 and deactivation kinetics (Furukawa et al., 2005) , though such Y535 repositioning occurs in the case of both GNE-6901 and GNE-8324 binding (Hackos et al., 2016) . Nonetheless, the fact that different modulators that bind to the GluN1-GluN2A subunit interface within the LBD can have such distinct effects on channel function indicate the future value of this binding site for selectively modulating NMDARs via diverse mechanisms.
Consequences of subtype selectivity
While many of the specific PAMs discussed do not represent fully drug-like molecules due to limitation of potency, solubility, pharmacokinetics, and potential off target effects, these classes of PAMs demonstrate the diversity of properties that could be found in a potential drug (Table 1) . One key determinant of the consequences of in vivo PAM treatment will be the GluN2 subunit selectivity. For example potentiation of 2A and 2B containing NMDARs could have broad effects throughout the brain given the widespread expression of these subunits in the adult. GluN2A NMDARs in particular could enhance synaptic function throughout cortico-limbic areas as these NMDARs are found at synapses in the form of both di-heteromeric GluN1/2A/2A and tri-heteromeric GluN1/2A/2B NMDARs (Gray et al., 2011; Rauner and Kohr, 2011; Soares and Lee, 2013; Tovar et al., 2013) . While di-heteromeric GluN1/2B/2B NMDARs are found at extrasynaptic locations in excitatory pyramidal neurons (Harris and Pettit, 2007; Papouin et al., 2012) , these receptors have synaptic functions in interneurons (Hanson et al., 2013) . Thus PAMs that affect GluN2B-containing NMDARs should also have broad effects.
Arguments could be made for or against the desirability of potentiating GluN2B subunits. On one hand, transgenic overexpression of GluN2B results in mice with enhanced synaptic plasticity and learning and memory (Tang et al., 1999; Wang et al., 2009) , which could suggest value in enhancing GluN2B function. However it's important not to equate the effects of over-expression with pharmacological enhancement. As the cytoplasmic tail of GluN2B NMDAR participates in organization of the postsynaptic complex and plays critical roles in signaling (Foster et al., 2010; Martel et al., 2012; Sheng and Pak, 1999) , increasing the abundance of this subunit beginning during early development could have very different effects than pharmacologically enhancing receptors with endogenous subunit compositions. At the same time, data using GluN2B antagonists which are much more effective on GluN1/2B/2B diheteromers compared to GluN1/2A/2B triheteromers Hatton and Paoletti, 2005; Stroebel et al., 2014) , has implicated GluN2B-containing NMDARs in mediating excitotoxic cell damage and death Liu et al., 2007; Ronicke et al., 2011; Zeron et al., 2002) . Hypothesis for the damaging effects of GluN2B NMDAR over-activation include preferential coupling of GluN2B-containing NMDARs to signaling pathways involved in cell death, and/or the preferential extrasynaptic location of these receptors (Hardingham and Bading, 2010; Martel et al., 2012; Zhou and Sheng, 2013) . Thus the in vivo consequences of potentiating GluN2B subunit-containing NMDARs could involve a mixture of effects on synaptic triheteromers and extrasynaptic diheteromers, with theoretical bases for both beneficial and deleterious consequences.
Interestingly, human genetics implicates both GluN2A and GluN2B in various conditions including attention deficit hyperactivity disorder, autism spectrum disorder, epilepsy, intellectual disability, and schizophrenia (Yuan et al., 2015) . In particular, the numerous GluN2A mutations that have been found in epilepsyaphasia syndromes provide interesting insight. While some GluN2A mutations are clearly loss-of-function, studies focusing on missense mutations of residues with expected roles in NMDAR activation have demonstrated multiple examples of gain-offunction (Carvill et al., 2013; Lemke et al., 2013; Lesca et al., 2013; Marwick et al., 2015; Serraz et al., 2016; Yuan et al., 2014) . That both loss-or gain-of-function of GluN2A mutations can lead to epilepsy suggests that while GluN2A potentiation could be beneficial in cases of NMDAR hypofunction, negative consequences of excessive potentiation could also be possible.
While GluN2A and GluN2B are widely distributed in the adult brain, the more restricted distribution of GluN2C and GluN2D in subcortical and brainstem structures suggest the consequences of PAMs targeting these subunits will be more specific. For example CIQ delivery to the amygdala facilitates the retention of fear and extinction learning in mice , and delivery to the subthalamic nucleus (STN) can enhance STN neuron spike rates in vivo (Swanger et al., 2015) . This suggests GluN2C/D potentiation could both enhance emotional memory via the amygdala, and alter function of basal ganglia circuitry, which could potentially be beneficial in the context of movement disorders like Parkinson's disease.
While cortical and hippocampal excitatory neuron expression is restricted to GluN2A and GluN2B, there is evidence for expression of all four GluN2 subunits in forebrain interneurons (Monyer et al., 1994) . Furthermore, functional roles for synaptic GluN2A and GluN2B have been shown in interneurons (Hackos et al., 2016; Hanson et al., 2013) and functional roles for interneuron GluN2C and GluN2D are also likely. For example, the expression of GluN2C and GluN2D in interneurons could explain the ability of systemic CIQ treatment to oppose the behavioral impacts of treatment with the psychotomimetic NMDAR pore blocker MK-801 (Suryavanshi et al., 2014) , which can alter circuit function via reduction of interneuron activation (Homayoun and Moghaddam, 2007) . Thus activation of GluN2A, GluN2B, GluN2C, or GluN2D-containing NMDARs could all potentially boost inhibition and be of potential use in cases of interneuron hypofunction. In addition to schizophrenia (Gonzalez-Burgos and Lewis, 2012) , interneuron hypofunction has been identified as driving pathophysiology in animal models of epilepsy, and Alzheimer's disease (Verret et al., 2012; Yamakawa, 2009) . Therefore interneurons should be considered as potential key targets of NMDAR PAM action.
Consequences of type I vs type II PAM effects
While existing data contrasting PAMs with Type I vs Type II effects is limited, it is interesting to consider potential differences in physiological impacts that could arise from the different types of PAM effects. A key difference between the types of PAMs is that PAMs dominated by type I effects could better maintain the temporal fidelity of NMDAR signaling because they don't slow deactivation like PAMs with strong type II effects. In theory, a longerlasting NMDAR ESPC might deleteriously affect the fidelity of synaptic timing, especially in situations with high frequency synaptic activity, such as during network oscillations. Another difference is that while PAMs with type I effects should enhance the peak synaptic current regardless of agonist concentrations, PAMs with purely type II effects should be unable to enhance peak currents at synapses where agonist concentrations are saturating during synaptic transmission. At the same time the observation that the potency of a PAM with type II effects can be dependent on the Glu concentration (Hackos et al., 2016) could also contribute to differences in PAM effects at different synapses. In particular, synapses with high resting Glu levels could allow such PAMs to bind prior to synaptic transmission. Thus both resting and peak synaptic Glu concentration levels could influence the efficacy of PAMs with type II effects. As Glu transporter density varies throughout brain regions (Bar-Peled et al., 1997) , and can even vary at synapses made by the same neuronal population onto different postsynaptic target populations (Chaudhry et al., 1995) , it is possible that synaptic Glu concentration profiles vary between different types of synapses. Therefore there is potential for PAMs with type II effects that depend on Glu concentration to have variable profiles of action across different synapses.
A striking example of synapse-dependent effects is the mixed type I/II GluN2A PAM GNE-8324 that binds with higher potency at high Glu concentrations (Hackos et al., 2016) . This property suggests much lower PAM concentrations could be effective at synapses where ambient Glu levels are higher and therefore allow higher levels of PAM binding prior to synaptic Glu release. Strikingly, at concentrations tested in vitro, GNE-8234 potentiates synapses on hippocampal interneurons, but not pyramidal neurons, while a PAM dominated by type I PAM effects, GNE-6901 (which lacks a pronounced dependence of PAM affinity on Glu concentration) potentiates both type of synapses equally. This is consistent with the hypothesis that hippocampal interneuron synapses have higher resting Glu concentrations, resulting in greater GNE-8324 effects. The differential effects of the PAMs was also manifest at the circuit level: While GNE-6901 could enhance synaptic plasticity of synapses onto pyramidal neurons, GNE-8324 impaired synaptic plasticity, apparently due to the dominance of the effects on interneurons which can oppose synaptic plasticity induction via polysynaptic inhibition (Hackos et al., 2016) . Consistent with the ability of PAMs with type I PAM effects to have impacts that are dominated by robust effects on pyramidal neurons, LTP is enhanced Fig. 5 . GNE-6901 vs GNE-8324 properties. a. GNE-6901 is a GluN2A-selective PAM dominated by type I effects, showing enhancement of Glu-activated currents without significantly slowing deactivation kinetics. b. GNE-8324 is a GluN2A-selective mixed type I/II PAM that slows deactivation kinetics. c. GNE-6901 alters peak currents without significantly shifting the Glu EC50. d. As expected for a PAM with both type I and type II activities, GNE-8324 both enhances peak current and shifts the Glu EC50 to the left. Table 1 Properties of different NMDAR PAMs. The selectivity profile, type of PAM effects, and sites of action for the key PAMs described in this review are listed. As described in the text, PAMs with purely type I PAM effects are defined as modulating the maximal current while PAMs dominated by type II effects modulate agonist EC50 and slow deactivation. Cases where robust Type I or Type II effects have been demonstrated are specified. Sites of action are only specified when binding sites are especially well defined by mutational analysis (or by a co-crystal structure as in the case of the GNE compounds). by oxysterols (Paul et al., 2013) . While LTP enhancement could be desirable in some disease contexts, in theory PAMs that could selectively enhance interneuron function could also be beneficial in the context of diseases associated with interneuron hypofunction, which as discussed include schizophrenia, epilepsy and Alzheimer's disease (Gonzalez-Burgos and Lewis, 2012; Verret et al., 2012; Yamakawa, 2009) . Along with some potential benefits, there are also undesirable consequences of the type II mode of action. In addition to degrading temporal fidelity of NMDAR signaling, another potentially negative consequence of the type II PAM effect is that shifting agonist EC50 could lead to over-activation of NMDARs by ambient Glu. In the extreme case, given sufficiently high ambient Glu and a sufficiently large EC50 shift, a PAM dominated by type II effects could act like an agonist. In fact with GNE-8324, in cell-line experiments, we observed some degree of agonist-like activity in the presence of Gly prior to Glu application (Hackos et al., 2016) . In practice it is very difficult to distinguish true agonist activity of a compound from activation by low levels of contaminating agonist when PAM binding makes NMDAR more sensitive to Glu. Regardless of this distinction, it is clear that causing large fold shifts of the agonist EC50 should be sufficient to cause a PAM to act like an agonist under physiological conditions, as some level of ambient agonist will be present in most circumstances. This undesirable aspect of the type II PAM effect has been observed with mGluR5 PAMs, where low fold shift compounds achieve a better therapeutic index while high fold shift compounds cause seizures (Yang et al., 2016) . As a mechanism of mGluR5 PAM efficacy is proposed to be enhancing NMDAR function, it will be interesting to test if a similar relationship between fold shift (degree of type II activity) and therapeutic index exists for NMDAR PAMs.
Conclusions future directions
Overall the increasing number NMDAR PAM classes that have been discovered has opened up possibilities for the design of therapeutics that target NMDARs in situations where hypofunction of these receptors drives neurological dysfunction. While distinct binding sites allow for diverse subunit selectivity profiles, it is clear that not only subunit selectivity, but also the nature of PAM action (type I vs. type II vs. mixed type I/II) will have major consequences on the impacts of PAMs in brain circuits. As existing PAMs are characterized and more PAMs are discovered, it will be critical to examine the properties of potentiation, including PAM effects on deactivation and agonist EC50s, and to correlate these properties with effects at the levels of circuit function and behavior. Beyond the simple attributes of type I and type II effects, mechanistic information from single channel recordings and detailed kinetic models will also be needed to provide additional information into PAM mechanisms of action. Deep understanding of PAM binding sites and mechanisms of action will provide the tools necessary to enable custom design of NMDAR PAMs with the particular properties best suited to their therapeutic application. Ultimately distinct profiles of subunit selectivity and potentiation mode may be required to have the best safety and efficacy profile in the context of different indications.
